<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473613</url>
  </required_header>
  <id_info>
    <org_study_id>Ashraf Elmantwe 1</org_study_id>
    <nct_id>NCT03473613</nct_id>
  </id_info>
  <brief_title>Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention</brief_title>
  <official_title>Comparison of Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention:Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian
      hyperstimulation syndrome in context of assisted reproductive technologies aiming in its
      prevention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women undergoing in vitro fertilization or intracytoplasmic sperm injection whom were at high
      risk for developing ovarian hyperstimuation syndrome were received either oral
      Cabergoline.5mg tablets for 7days starting on ovum pick up day and continued for 7days or
      received 10ml of 10%calcium gluconate in 200ml normal saline on ovum pick up day and
      continued for 4days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2014</start_date>
  <completion_date type="Actual">April 15, 2017</completion_date>
  <primary_completion_date type="Actual">April 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of ovarian hyperstimuation syndrome</measure>
    <time_frame>20 days from ovum pick up day</time_frame>
    <description>Clinical condition occurred in context of assisted reproductive technologies in which there serous sacs fluid accumulation and hemoconcentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Types of ovarian hyperstimuation syndrome and severity</measure>
    <time_frame>20 days from ovum pick up day</time_frame>
    <description>Clinical severity either mild ,moderate or severe and its type either early or late onst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemical pregnancy</measure>
    <time_frame>14 day from embryos transfer day</time_frame>
    <description>Positive human chorionic Gonadotropin in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>5 week from embryos transfer day</time_frame>
    <description>Intrauterine gestational sac</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Ovarian Hyperstimulation</condition>
  <arm_group>
    <arm_group_label>Calcium infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10ml 10%calcium gluconate in 200ml normal saline solution given intravenously over thirty minutes, on ovum pick up day and continued for 4days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Cabergoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving oral Cabergoline (cabergamon 0.5 milligram tablet ) from ovum pick up day and continued for 7days,once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Cabergoline</intervention_name>
    <description>Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days</description>
    <arm_group_label>Oral Cabergoline</arm_group_label>
    <other_name>Cabergamon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Gluconate</intervention_name>
    <description>Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days</description>
    <arm_group_label>Calcium infusion</arm_group_label>
    <other_name>Calcium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women undergoing assisted reproductive technologies whom at high risk for developing
             ovarian hyperstimulation syndrome as with high basal antimullerian hormone ,excess
             antral follicular count ,high seum estradiol on day of humian choronic gonadotrophin

        Exclusion Criteria:women with other endocrinopathy as congenital adrenal hyperplasia ,
        hyperprolactinemia,diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women undergoing assisted reproductive technologies</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashraf N Elmantwe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benha University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ashraf nassif Elmantwe</name>
      <address>
        <city>Cairo</city>
        <state>Elqalopia</state>
        <zip>5131</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>ashraf nassif mahmoud elmantwe,MD</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Calcium infusion</keyword>
  <keyword>Cabergoline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Contact investigators</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

